title: Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.
abstract: BACKGROUND
  Pantoprazole is a new substituted benzimidazole which inhibits gastric H+,K(+)-ATPase.
  
  
  METHODS
  In this double-blind, multicentre study, pantoprazole 40 mg once daily was compared with omeprazole 20 mg once daily in the treatment of grade II and III (Savary-Miller) reflux oesophagitis. Endoscopy was repeated after 4 weeks of treatment, and also after 8 weeks in patients unhealed at 4 weeks.
  
  
  RESULTS
  The primary efficacy variable was ulcer healing; after 4 weeks, 81/103 (78.6%) patients in the pantoprazole group and 83/105 (79.0%) patients in the omeprazole group had healed completely. After 8 weeks, the cumulative healing rates were 94.2% and 91.4% in the pantoprazole and omeprazole groups, respectively (P > 0.05 at 4 weeks and 8 weeks). Both groups experienced rapid relief of the key symptoms: heartburn, acid regurgitation and pain on swallowing. The time course of relief of the individual symptoms was similar in both groups after 2 and 4 weeks (P > 0.05). Both treatments were well tolerated, with only three patients withdrawing owing to adverse events.
  
  
  CONCLUSIONS
  Pantoprazole has been shown to be as effective as omeprazole in the treatment of reflux oesophagitis.
authors.affiliation: Ospedale S. Orsola, Bologna, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Corinaldesi
authors.forename: M
authors.initials: M
authors.lastname: Valentini
authors.forename: J
authors.initials: J
authors.lastname: Belaïche
authors.forename: R
authors.initials: R
authors.lastname: Colin
authors.forename: H
authors.initials: H
authors.lastname: Geldof
authors.forename: C
authors.initials: C
authors.lastname: Maier
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D000077402:Pantoprazole; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole